FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377010946> ?p ?o ?g. }

• W4377010946 abstract "Viral oncolytic immunotherapy is a nascent field that is developing tools to direct the immune system to find and eliminate cancer cells. Safety is improved by using cancer-targeted viruses that infect or grow poorly on normal cells. The recent discovery of the low-density lipoprotein (LDL) receptor as the major vesicular stomatitis virus (VSV) binding site allowed for the creation of a Her2/neu-targeted replicating recombinant VSV (rrVSV-G) by eliminating the LDL receptor binding site in the VSV-G glycoprotein (gp) and adding a sequence coding for a single chain antibody (SCA) to the Her2/neu receptor. The virus was adapted by serial passage on Her2/neu-expressing cancer cells resulting in a virus that yielded a 15- to 25-fold higher titer following in vitro infection of Her2/neu+-expressing cell lines than that of Her2/neu-negative cells (~1 × 108/mL versus 4 × 106 to 8 × 106/mL). An essential mutation resulting in a higher titer virus was a threonine-to-arginine change that produced an N-glycosylation site in the SCA. Infection of Her2/neu+ subcutaneous tumors yielded >10-fold more virus on days 1 and 2 than Her2/neu- tumors, and virus production continued for 5 days in Her2/neu+ tumors compared with 3 days that of 3 days in Her2/neu- tumors. rrVSV-G cured 70% of large 5-day peritoneal tumors compared with a 10% cure by a previously targeted rrVSV with a modified Sindbis gp. rrVSV-G also cured 33% of very large 7-day tumors. rrVSV-G is a new targeted oncolytic virus that has potent antitumor capabilities and allows for heterologous combination with other targeted oncolytic viruses. IMPORTANCE A new form of vesicular stomatitis virus (VSV) was created that specifically targets and destroys cancer cells that express the Her2/neu receptor. This receptor is commonly found in human breast cancer and is associated with a poor prognosis. In laboratory tests using mouse models, the virus was highly effective at eliminating implanted tumors and creating a strong immune response against cancer. VSV has many advantages as a cancer treatment, including high levels of safety and efficacy and the ability to be combined with other oncolytic viruses to enhance treatment results or to create an effective cancer vaccine. This new virus can also be easily modified to target other cancer cell surface molecules and to add immune-modifying genes. Overall, this new VSV is a promising candidate for further development as an immune-based cancer therapy." @default.
• W4377010946 created "2023-05-19" @default.
• W4377010946 creator A5013107164 @default.
• W4377010946 creator A5072077598 @default.
• W4377010946 date "2023-06-29" @default.
• W4377010946 modified "2023-10-01" @default.
• W4377010946 title "Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors" @default.
• W4377010946 cites W1542691850 @default.
• W4377010946 cites W1969914406 @default.
• W4377010946 cites W1970508752 @default.
• W4377010946 cites W1997505475 @default.
• W4377010946 cites W2014568747 @default.
• W4377010946 cites W2033624540 @default.
• W4377010946 cites W2038269723 @default.
• W4377010946 cites W2040052147 @default.
• W4377010946 cites W2057236391 @default.
• W4377010946 cites W2099682829 @default.
• W4377010946 cites W2124160523 @default.
• W4377010946 cites W2128008808 @default.
• W4377010946 cites W2150701651 @default.
• W4377010946 cites W2151707767 @default.
• W4377010946 cites W2155322419 @default.
• W4377010946 cites W2156268169 @default.
• W4377010946 cites W2157046375 @default.
• W4377010946 cites W2166433072 @default.
• W4377010946 cites W2337495228 @default.
• W4377010946 cites W2466572871 @default.
• W4377010946 cites W2494461917 @default.
• W4377010946 cites W2561037714 @default.
• W4377010946 cites W2615746750 @default.
• W4377010946 cites W2749158376 @default.
• W4377010946 cites W2770961735 @default.
• W4377010946 cites W2778202787 @default.
• W4377010946 cites W2784318462 @default.
• W4377010946 cites W2789413292 @default.
• W4377010946 cites W2793196316 @default.
• W4377010946 cites W2902292062 @default.
• W4377010946 cites W2958271298 @default.
• W4377010946 cites W2984628891 @default.
• W4377010946 cites W2987401578 @default.
• W4377010946 cites W3078580085 @default.
• W4377010946 cites W3080269137 @default.
• W4377010946 cites W3157441828 @default.
• W4377010946 cites W4281260924 @default.
• W4377010946 cites W4309731128 @default.
• W4377010946 doi "https://doi.org/10.1128/jvi.00372-23" @default.
• W4377010946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37199666" @default.
• W4377010946 hasPublicationYear "2023" @default.
• W4377010946 type Work @default.
• W4377010946 citedByCount "1" @default.
• W4377010946 countsByYear W43770109462023 @default.
• W4377010946 crossrefType "journal-article" @default.
• W4377010946 hasAuthorship W4377010946A5013107164 @default.
• W4377010946 hasAuthorship W4377010946A5072077598 @default.
• W4377010946 hasConcept C104317684 @default.
• W4377010946 hasConcept C121608353 @default.
• W4377010946 hasConcept C159047783 @default.
• W4377010946 hasConcept C159654299 @default.
• W4377010946 hasConcept C203014093 @default.
• W4377010946 hasConcept C22070199 @default.
• W4377010946 hasConcept C2522874641 @default.
• W4377010946 hasConcept C2776438120 @default.
• W4377010946 hasConcept C2776872082 @default.
• W4377010946 hasConcept C2777343345 @default.
• W4377010946 hasConcept C2778199166 @default.
• W4377010946 hasConcept C2779057330 @default.
• W4377010946 hasConcept C2910348395 @default.
• W4377010946 hasConcept C32611913 @default.
• W4377010946 hasConcept C530470458 @default.
• W4377010946 hasConcept C54355233 @default.
• W4377010946 hasConcept C55493867 @default.
• W4377010946 hasConcept C67705224 @default.
• W4377010946 hasConcept C82210918 @default.
• W4377010946 hasConcept C86803240 @default.
• W4377010946 hasConceptScore W4377010946C104317684 @default.
• W4377010946 hasConceptScore W4377010946C121608353 @default.
• W4377010946 hasConceptScore W4377010946C159047783 @default.
• W4377010946 hasConceptScore W4377010946C159654299 @default.
• W4377010946 hasConceptScore W4377010946C203014093 @default.
• W4377010946 hasConceptScore W4377010946C22070199 @default.
• W4377010946 hasConceptScore W4377010946C2522874641 @default.
• W4377010946 hasConceptScore W4377010946C2776438120 @default.
• W4377010946 hasConceptScore W4377010946C2776872082 @default.
• W4377010946 hasConceptScore W4377010946C2777343345 @default.
• W4377010946 hasConceptScore W4377010946C2778199166 @default.
• W4377010946 hasConceptScore W4377010946C2779057330 @default.
• W4377010946 hasConceptScore W4377010946C2910348395 @default.
• W4377010946 hasConceptScore W4377010946C32611913 @default.
• W4377010946 hasConceptScore W4377010946C530470458 @default.
• W4377010946 hasConceptScore W4377010946C54355233 @default.
• W4377010946 hasConceptScore W4377010946C55493867 @default.
• W4377010946 hasConceptScore W4377010946C67705224 @default.
• W4377010946 hasConceptScore W4377010946C82210918 @default.
• W4377010946 hasConceptScore W4377010946C86803240 @default.
• W4377010946 hasIssue "6" @default.
• W4377010946 hasLocation W43770109461 @default.
• W4377010946 hasLocation W43770109462 @default.
• W4377010946 hasOpenAccess W4377010946 @default.
• W4377010946 hasPrimaryLocation W43770109461 @default.
• W4377010946 hasRelatedWork W1645018133 @default.

• next